<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637075</url>
  </required_header>
  <id_info>
    <org_study_id>GK-PET/MR Tü-014</org_study_id>
    <nct_id>NCT03637075</nct_id>
  </id_info>
  <brief_title>Raclopride-PET/MRT</brief_title>
  <official_title>Characterization of Insulin Action and Dopamine-signaling in the Human Brain of Normal Weight and Obese Subjects by [11C]-Raclopride-PET/MRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral insulin resistance plays an important role in the development of obesity and
      diabetes mellitus type 2. The aim of this project is to examine the effect of human nasal
      insulin on the dopaminergic system. Therefore, characteristics of cerebral dopamine receptors
      before and after administration of nasal insulin vs. placebo shall be analyzed in a
      randomized way. Moreover, the investigators plan to examine the insulin action on cortical
      and subcortical activation in humans and the interaction of dopamine metabolism with
      [11C]-Raclopride-PET/MRI. By performing fMRI measurements, insulin sensitivity of the central
      nervous system can be investigated simultaneously. Recruiting is planed as a two-step
      process.First 12 normal-weight (BMI 20-25 kg/m²) men should be examined. If first results
      show a insulin-dependent effect on the availability of dopamine receptors in the human brain,
      recruitment of 12 overweight men will get started.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>single-blinded, monocentric, prospective crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of nasal insulin vs. placebo on the insulin sensitivity of the human brain as well as effects on regional availability of dopamine receptors.</measure>
    <time_frame>0-60 min</time_frame>
    <description>assessed by fMRI (insulin sensitivity of the brain measured as change in regional brain activity and Raclopride-PET/MRT (regional dopamine receptor availability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between normalweight and overweight subjects regarding insulin sensitivity and availability of dopamine receptors</measure>
    <time_frame>0 - 60 min</time_frame>
    <description>assessed by fMRI and Raclopride-PET/MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of nasal insulin vs. placebo on changes in plasma insulin levels</measure>
    <time_frame>0 - 60min</time_frame>
    <description>assessed by blood sampling after application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of nasal insulin vs. placebo on changes in plasma glucose levels</measure>
    <time_frame>0 - 60min</time_frame>
    <description>assessed by blood sampling after application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of nasal insulin vs. placebo on changes in FFA levels</measure>
    <time_frame>0 - 60min</time_frame>
    <description>assessed by blood sampling after application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of nasal insulin vs. placebo on changes in prolactin levels as a proxy for the dopaminergic tonus</measure>
    <time_frame>0 - 60min</time_frame>
    <description>assessed by blood sampling after application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of nasal insulin vs. placebo on changes in autonomic nervous system</measure>
    <time_frame>-30 - 60 min</time_frame>
    <description>assessed by heart rate variability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal placebo administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal insulin administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intranasal insulin</intervention_name>
    <description>intranasal administration of insulin (160 IU)</description>
    <arm_group_label>Intranasal insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo intranasal administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures.

          -  Intake of any medication

          -  HbA1C &lt;6%

          -  BMI 20-25 kg/m²

          -  Clinical routine blood parameters within the normal ranges

          -  All participants must agree to get informed of unexpected detected, clinical relevant
             findings.

        Exclusion Criteria:

          -  Acute diseases such as infections (e.g.)

          -  Any relevant cardiovascular disease

          -  Any surgery within the last three months

          -  Any neurologic or psychiatric disease

          -  Known allergies

          -  Hb &lt; 13 g/dl

          -  Presence of any contraindication for the conduct of an MRI investigation, such as
             cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system,
             metallic splinters in the eye, ferromagnetic or electronically operated active devices
             like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve
             stimulators, prosthetic heart valves etc.

          -  Claustrophobia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29 82714</phone>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tuebingen, Department of Internal Medicine IV</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus, Type 2</keyword>
  <keyword>cerebral insulin resistance</keyword>
  <keyword>insulin action in the human brain</keyword>
  <keyword>dopamine signalling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

